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92 Early treatment with inhaled antibiotics postpones recurrence of
Achromobacter species in cystic ﬁbrosis
M. Wang1, W. Ridderberg1, C.R. Hansen2, N. Høiby2, S. Jensen-Fangel1,
H.V. Olesen1, M. Skov2, L.E. Lemming1, T. Pressler2, H.K. Johansen2,
N. Nørskov-Lauritsen1. 1Aarhus University Hospital, Aarhus, Denmark;
2Rigshospitalet, University of Copenhagen, Copenhagen, Denmark
Objectives: In this nationwide retrospective study, we analysed early acquisition
of Achromobacter spp. in Danish cystic ﬁbrosis (CF) patients from 2000 to 2011,
excluding cross-infections.
Methods: Thirty-four primary isolates were identiﬁed by partial sequencing of
recA, tyrB and icd, and were subjected to extended antimicrobial susceptibility
testing. Achromobacter xylosoxidans accounted for 13 (38%) of the isolates, and an
unnamed species, tentatively designated MLSA cluster III, accounted for 11 (32%)
of the isolates.
Antimicrobial susceptibility testing showed that meropenem, piperacillin–
tazobactam and trimethoprim/sulfamethoxazole were highly active against
chemotherapy-naı¨ve Achromobacter, while ceftazidime, colistin and tobramycin
were judged to have adequate activity for inhalation therapy.
We assessed effectiveness of early antimicrobial treatment by a Kaplan–Meier
estimation of time to recurrence of Achromobacter spp. A signiﬁcant difference
was observed between 25 patients treated with inhaled ceftazidime, colistin, or
tobramycin, and 22 patients who did not receive inhaled antibiotics: three years after
primary acquisition, 55% of treated patients remained free of Achromobacter spp.,
in contrast to 17% of untreated patients.
Conclusion: Our ﬁndings suggest that early treatment with inhaled antibiotics may
prevent or postpone chronic infection with Achromobacter species in CF patients.
93 Aztreonam lysine for inhalation as a treatment for Burkholderia
cepacia complex in CF
J. Willekens1, E. De Wachter1, I. De Schutter1, E. Vanderhelst1, L. De Meirleir1,
A. Malfroot1. 1Universitair Ziekenhuis Brussel, Cystic Fibrosis Clinic, Brussels,
Belgium
Objectives: Aztreonam lysine for inhalation (AZLI) has been proven effective in
the treatment of chronic Ps. aeruginosa (PA) infection in CF. It is not clear whether
patients with other infecting organisms, such as B. cepacia complex (Bcc), could
beneﬁt from this treatment. We aim to investigate the clinical efﬁcacy of AZLI for
Bcc in CF.
Methods: We reviewed medical ﬁles of 4 patients infected with B. multivorans who
were treated with AZLI. Bcc prevalence in Belgium is 2%.
Results: The patients were 26 (A, male, severe liver disease and portal hyperten-
sion), 33 (B female), 14 (C, female, CFRD) and 12 (D, male) years old. A was
infected for several years, whereas B, C and D were newly acquired colonisations.
A and B had co-infection with PA. A, B and C were treated for 48 weeks with AZLI
(28 day on/off cycle) as add-on therapy to another cyclical inhaled antibiotic, D for
12 weeks continuously as mono-inhaled therapy. In addition, A received 3-monthly
courses of IV antibiotics; B, C and D had 1 IV course at time of acquisition.
Mean lung function values remained stable for 48 weeks during AZLI. D showed
a slight improvement in FEV1 of 4% after 12 weeks. A did not deteriorate further.
In B and D, Bcc was not found in the respiratory cultures during AZLI inhalation.
However in D, Bcc reappeared after AZLI was stopped. B and C had less pulmonary
exacerbations after start of AZLI. No adverse effects were seen.
Conclusion: These Bcc-infected patients seem to beneﬁt from a treatment with
AZLI. In 2 recent acquisitions, eradication of B. multivorans was seen. AZLI was
well tolerated, also in young patients. Clinical trials studying the efﬁcacy of AZLI
for Bcc are ongoing.
94 The interaction of liposomal tobramycin-bismuth with lung cells:
Fusion efﬁcacy and toxicity studies
F.N. Tshimanga1, A. Omri1. 1Laurentian University, Chemistry/Biochemistry,
Sudbury, Canada
Objectives: Pseudomonas aeruginosa pulmonary infection is a main cause of illness
and death for patients with cystic ﬁbrosis. P. aeruginosa is also intrinsically resistant
to many antimicrobial agents. This resistance has been attributed to its efﬂux
capabilities, its impermeable outer membrane, its tendency to colonize surfaces
as a bioﬁlm, and its ability to acquire and maintain antibiotic resistance-encoding
plasmids. There is pressing demands for novel strategies for targeting infections
in cystic ﬁbrosis lung patients. Recent studies by our group have shown the effec-
tiveness of a liposomal tobramycin-bismuth (lipo Tob-Bi) formulation to eradicate
P. aeruginosa. However, preliminary studies have shown that concentrations of free
Tob-Bi inhibit lung cell growth and exhibit cytotoxicity.
Methods: Using different approaches like light microscopy (cell morphology),
cell titer blue and protein assays (cell viability), DAPI staining and ﬂuorescence
microscopy (DNA damage), autometallography (bismuth deposition) and ﬂow
cytometry (effect on cell growth) in A549 cell lines. A reduction of cell growth,
an increased bismuth deposition, and DNA damage in presence of free Tob-Bi
compared to the liposomal formulation.
Conclusion: This research work has a high potential to lead to new insights re-
garding novel and innocuous therapies to combat cystic ﬁbrosis relevant infections.
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Objectives: Ceftazidime (CAZ) remains one of the main anti-infective agents against P. aeruginosa
in cystic ﬁbrosis patients. Caregivers reported various disturbing phenomena of intolerance, especially
in case of prolonged infusion. A spontaneous production of pyridine (P), which is a toxic product,
raises some concern. Our aim was to study the kinetics of spontaneous degradation of CAZ shaped
in Portable Infusion Pumps (PIPs) and the potential risk of exposure to P.
Methods: 18 PIPs LV10 Baxter® were ﬁlled by 12g of CAZ diluted in 230mL of saline solution
(52.17mg/mL). Devices were stored either at 4, 22, or 33ºC. Samples were collected immediately
before and then every 4 hrs after the shaping of PIPs until the 24th h. Both CAZ and P were analysed
by HPLC. Model-independent kinetic parameters were determined for both CAZ and P (Table 1).
Results: See Table 1.
Table 1.
Storage temperature of PIPsa 4ºC (n = 6) 22ºC (n = 6) 33ºC (n = 6)
Compound CAZ Pyridine CAZ Pyridine CAZ Pyridine
Final concentration (mg/mL) 51.7±2.3 0.133±0.066 46.1±1.0 0.425±0.015 43.0±2.0 0.790±0.007
Terminal half-life (h) 312.4±66.3 −21.6±8.0 88.6±17.2 −10±0.3 76.8±8.8 −6.7±0.1
Total delivered amount 7.5±0.1 g 15.6±0.7mg 11.6±0.3 g 55.7±0.1mg 10.8±0.5 g 91.5±0.1mg
Remaining volume after
24 hrs into the PIPs (mL)
80.5±7.1 <1.0 <1.0
Data are mean±SD.
aThe ﬂow controller of the devices was maintained at 33ºC.
Conclusions: Taking into account the unavoidable presence of P in the medium, we suggest:
a. to avoid exposing a solution of CAZ to over 22ºC, especially in cases of prolonged infusion,
b. to replace the once daily administration schedule by a twice daily infusion: 6 g/12 hrs leads to a
theoretical production of ~36mg (vs. ~56mg) of P per day of treatment at 22ºC.
Other options to be tested are a decrease of the daily dose of CAZ and maintaining PIPs at 4ºC.
